Pitfalls in the diagnosis of a tumefactive demyelinating lesion: A case report

<p>Abstract</p> <p>Introduction</p> <p>In rare instances, demyelinating disorders manifest as tumefactive lesions that simulate brain tumors. We report a patient with a space-occupying lesion in the parietal lobe, which presented a serious diagnostic dilemma, between a rare tumefactive demyelinating disease, such as Balo concentric sclerosis and a glioma. This case report highlights important diagnostic clues in the differential diagnosis of Balo concentric sclerosis.</p> <p>Case presentation</p> <p>A 20-year-old Caucasian woman with acute onset of left-sided weakness and numbness was admitted to hospital with neurologic signs of left-sided hemiparesis and hypoesthesia. Brain magnetic resonance imaging showed a mass lesion of abnormal signal intensity with concentric enhancing rings in the right parietal lobe, without perifocal edema. The characteristic concentric pattern detected on the magnetic resonance images was highly suggestive of Balo disease, and corticosteroids were administered. Evoked potentials, cerebrospinal fluid analysis, and magnetic spectroscopy findings were not specific, and glioma was also included in the differential diagnosis. A stereotactic biopsy was not diagnostic.</p> <p>After one month the patient showed moderate clinical improvement, and during 12 months follow-up, no further relapses occurred. In the follow-up magnetic resonance imaging, the concentric pattern had completely disappeared, and only a low-signal, gliotic lesion remained.</p> <p>Conclusion</p> <p>We hope this case presentation will advance our understanding of clinical and radiologic appearance of Balo concentric sclerosis, which is a rare demyelinating disease. Although this is a specific entity, it has a broader clinical impact across medicine, because it must be differentiated from other space-occupying lesions in the central nervous system.</p

Malignant neuroleptic syndrome following deep brain stimulation surgery: a case report

<p>Abstract</p> <p>Background</p> <p>The neuroleptic malignant syndrome is an uncommon but dangerous complication characterized by hyperthermia, autonomic dysfunction, altered mental state, hemodynamic dysregulation, elevated serum creatine kinase, and rigor. It is most often caused by an adverse reaction to anti-psychotic drugs or abrupt discontinuation of neuroleptic or anti-parkinsonian agents. To the best of our knowledge, it has never been reported following the common practice of discontinuation of anti-parkinsonian drugs during the pre-operative preparation for deep brain stimulation surgery for Parkinson's disease.</p> <p>Case presentation</p> <p>We present the first case of neuroleptic malignant syndrome associated with discontinuation of anti-parkinsonian medication prior to deep brain stimulation surgery in a 54-year-old Caucasian man.</p> <p>Conclusion</p> <p>The characteristic neuroleptic malignant syndrome symptoms can be attributed to other, more common causes associated with deep brain stimulation treatment for Parkinson's disease, thus requiring a high index of clinical suspicion to timely establish the correct diagnosis. As more centers become eligible to perform deep brain stimulation, neurologists and neurosurgeons alike should be aware of this potentially fatal complication. Timely activation of the deep brain stimulation system may be important in accelerating the patient's recovery.</p

Clinical, Neuroimaging, and Genetic Markers in Cerebral Amyloid Angiopathy-Related Inflammation: A Systematic Review and Meta-Analysis

Background: There are limited data regarding the prevalence of distinct clinical, neuroimaging and genetic markers among patients diagnosed with cerebral amyloid angiopathy-related inflammation (CAA-ri). We sought to determine the prevalence of clinical, radiological, genetic and cerebrospinal fluid biomarker findings in patients with CAA-ri. Methods: A systematic review and meta-analysis of published studies including patients with CAA-ri was conducted to determine the prevalence of clinical, neuroimaging, genetic and cerebrospinal fluid biomarker findings. Subgroup analyses were performed based on (1) prospective or retrospective study design and (2) CAA-ri diagnosis with or without available biopsy. We pooled the prevalence rates using random-effects models and assessed the heterogeneity using Cochran-Q and I2-statistics. Results: We identified 4 prospective and 17 retrospective cohort studies comprising 378 patients with CAA-ri (mean age, 71.5 years; women, 52%). The pooled prevalence rates were as follows: cognitive decline at presentation 70% ([95% CI, 54%-84%]; I2=82%), focal neurological deficits 55% ([95% CI, 40%-70%]; I2=82%), encephalopathy 54% ([95% CI, 39%-68%]; I2=43%), seizures 37% ([95% CI, 27%-49%]; I2=65%), headache 31% ([95% CI, 22%-42%]; I2=58%), T2/fluid-attenuated inversion recovery-hyperintense white matter lesions 98% ([95% CI, 93%-100%]; I2=44%), lobar cerebral microbleeds 96% ([95% CI, 92%-99%]; I2=25%), gadolinium enhancing lesions 54% ([95% CI, 42%-66%]; I2=62%), cortical superficial siderosis 51% ([95% CI, 34%-68%]; I2=77%) and lobar macrohemorrhage 40% ([95% CI, 11%-73%]; I2=88%). The prevalence rate of the ApoE (Apolipoprotein E) ϵ4/ϵ4 genotype was 34% ([95% CI, 17%-53%]; I2=76%). Subgroup analyses demonstrated no differences in these prevalence rates based on study design and diagnostic strategy. Conclusions: Cognitive decline was the most common clinical feature. Hyperintense T2/fluid-attenuated inversion recovery white matter lesions and lobar cerebral microbleeds were by far the most prevalent neuroimaging findings. Thirty-four percent of patients with CAA-ri have homozygous ApoE ϵ4/ϵ4 genotype and scarce data exist regarding the cerebrospinal fluid biomarkers and its significance in these patients

Microbleed Prevalence and Burden in Anticoagulant-Associated Intracerebral Bleed

Prior studies suggest an association between Vitamin K antagonists (VKA) and cerebral microbleeds (CMBs); less is known about nonvitamin K oral anticoagulants (NOACs). In this observational study we describe CMB profiles in a multicenter cohort of 89 anticoagulation-related intracerebral hemorrhage (ICH) patients. CMB prevalence was 51% (52% in VKA-ICH, 48% in NOAC-ICH). NOAC-ICH patients had lower median CMB count [2(IQR:1–3) vs. 7(4–11); P \u3c 0.001]; ≥5 CMBs were less prevalent in NOAC-ICH (4% vs. 31%, P = 0.006). This inverse association between NOAC exposure and high CMB count persisted in multivariable logistic regression models adjusting for potential confounders (OR 0.10, 95%CI: 0.01–0.83; P = 0.034)

Anticancer Gene Transfer for Cancer Gene Therapy

Gene therapy vectors are among the treatments currently used to treat malignant tumors. Gene therapy vectors use a specific therapeutic transgene that causes death in cancer cells. In early attempts at gene therapy, therapeutic transgenes were driven by non-specific vectors which induced toxicity to normal cells in addition to the cancer cells. Recently, novel cancer specific viral vectors have been developed that target cancer cells leaving normal cells unharmed. Here we review such cancer specific gene therapy systems currently used in the treatment of cancer and discuss the major challenges and future directions in this field

Anatomy of the human nucleus accumbens: A combined morphometric study

Purpose: The human nucleus accumbens (NA), which belongs to the basal ganglia of the brain, is the main part of the ventral striatum. The purpose of our clinically oriented anatomical-radiologic study was to provide anatomical and imaging data of the human NA, primarily useful to neurosurgeons. Methods: For our imaging study, we used cerebral magnetic resonance images (MRIs) from 26 neurosurgical patients (52 NAs). The material for our anatomic study consisted of 32 cerebral hemispheres (32 NAs) from 18 normal human brains which we have in our department (Department of Anatomy) from cadaver donors. We measured and analyzed the dimensions of the NA at specific clinically important transverse, coronal and sagittal levels. Results: The human NA suffers from age-related but no side- or sex-related morphometric changes. In surgically important stereotactic levels this nucleus is easily identifiable on MRIs. Conclusions: We present an anatomic guide of the NA from carefully measured data of our extensive and combined study and we hope that our work will be really helpful to neuroscientists interested in the NA. © 2010 Springer-Verlag

Stereotactic anatomy of the human nucleus accumbens: From applied mathematics to microsurgical accuracy

Purpose: Stereotactic surgery of the human NA is a neurosurgical achievement of the twenty-first century. Our purpose was to provide a clinically oriented study focused on the detailed stereotactic anatomy of the NA, with great respect to its targeting. We tried to offer a guide of NA stereotactic targeting for neurosurgeons. Methods: For our imaging study, we used cerebral magnetic resonance images (MRIs) from 26 neurosurgical patients (52 NAs). The material of our anatomic study consisted of 32 cerebral hemispheres (32 NAs) from 18 normal human brains, which we have in our Department (Department of Anatomy) from cadaver donors. We measured and analyzed the X, X′ , Y, Y′ , Z, Z′ stereotactic coordinates of the NA at specific clinically important transverse, coronal and sagittal levels. Results: Our principal findings contain a probability-based guide for in vivo (side depended) stereotactic localization of the human NA, a standard for the NA, specific stereotactic zone of the human brain (Z = -4), two specific standard NA areas (X = 7, X = 8) and the most reliable stereotactically standard area of the human NA (Y = 2). Conclusions: We provide a stereotactic anatomic guide for some common targeting necessities of the NA stereotactic surgery, resulted from detailed analysis and careful combination of the measured data of our clinically oriented study. We hope that our work will be a really useful guide for neurosurgeons applying deep brain stimulation of the NA. © 2011 Springer-Verlag

The human nucleus accumbens suffers parkinsonism-related shrinkage: A novel finding

Purpose: The human nucleus accumbens (NA) plays an important role in motivation and emotional processes and is involved in some of the most disabling neuropsychiatric disorders such as Parkinson&apos;s disease (PD). The purpose of our study was to check out the potential existence of a statistically significant difference in NA size between parkinsonian and non-parkinsonian individuals, through studying brain magnetic resonance images (MRIs). Methods: For our study we used 52 NAs from 26 cerebral MRIs from neurosurgical patients. Of these MRIs, 15 were preoperative from patients with advanced PD who underwent bilateral deep brain stimulation of the subthalamic nucleus. The group of non-parkinsonian MRIs came from the rest 11 individuals. We measured the absolute and relative NA maximum transverse diameter (D max), and absolute and relative NA width at a specific transverse plane. Results: We found a statistically significant difference of the mean value of the D max (absolute and relative) between the two groups. The mean percentage reduction of the NA size was 11.77% represented by the relative D max. Conclusions: To our knowledge, this is the first report of parkinsonism-related shrinkage of the human NA. Further research is needed to identify whether a respective shrinkage is also observed in patients with early PD and whether this atrophy is correlated with dopaminergic neuropsychiatric symptoms (perhaps mediated by a malfunctioning NA) that occur in PD. © 2011 Springer-Verlag